OPD footfall, surgery numbers dip in Kol – ET HealthWorld
Kolkata: There has been a drop in outpatient department (OPD) footfall across hospitals in Kolkata over the last fortnight. The dip in…
Browsing Tag
KOL
Rezolute KOL Event Highlights Significant Unmet Medical Need in Diabetic Macular…
<!-- Name:DistributionId Value:8794674 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
HTG Molecular Diagnostics Provides Highlights of its Second Event in Drug Discovery…
TUCSON, Ariz., Dec. 28, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative…
KOL Review of Lumos Pharma’s Interim Phase 2 Data Supports Potential for New Oral…
AUSTIN, Texas, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on rare disorders, hosted two key opinion leaders…
Vaccitech to Host KOL Webinar on the SNAPvax™ Platform for Inducing Tolerance to…
OXFORD, United Kingdom, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC) today announced that it will host a Key Opinion Leader (KOL) webinar on its SNAPvax™ Platform and…
CORRECTION — Aptose Presents Highlights from Corporate Update and KOL Event
HM43239 Delivers New Complete Remission at 160mg Dose in AML with Wildtype FLT3 New “G3” Formulation of Luxeptinib Demonstrates Encouraging PK Results SAN DIEGO and TORONTO, June…
Aptose Presents Highlights from Corporate Update and KOL Event
HM43239 Delivers New Complete Remission at 160mg Dose in AML with Wildtype FLT3 New “G3” Formulation of Luxeptinib Demonstrates Encouraging PK Results SAN DIEGO and TORONTO, June 02,…
Aptose to Provide Program Updates at KOL Webinar on Thursday, June 2nd
SAN DIEGO and TORONTO, May 25, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral…
Aileron Therapeutics to Host Virtual KOL Investor Event on May 19, 2022
BOSTON, May 13, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save…
Compass Therapeutics to Host Conference Call Highlighting Clinical Data from CTX-009
Call scheduled for Wednesday, May 4, 2022 at 8:00 a.m. ET Key Opinion Leader to Participate BOSTON, May 03, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a…